MedTrace Logo

Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

NCT06910098 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2025-04-04

No results posted yet for this study

Summary

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Conditions

  • LDL - Low Density Lipoprotein Receptor Disorder
  • Rosuvastatin

Interventions

DRUG

Rosuvastatin

a dose of 5mg were given and were compared for the cpk, ast and ldl levels

DRUG

Rosuvastatin

a dose of 10 mg were given and were compared for the cpk, ast and ldl levels

DRUG

Rosuvastatin

a dose of 20 mg were given and were compared for the cpk, ast and ldl levels

Sponsors & Collaborators

  • Central Park Medical College

    lead OTHER

Principal Investigators

  • Sikandar · Central Park Medical College

  • Sikandar · Central Park Medical College & Teaching Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-06-30
Completion
2024-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06910098 on ClinicalTrials.gov